» Articles » PMID: 20799351

Liver-specific Suppressor of Cytokine Signaling-3 Deletion in Mice Enhances Hepatic Insulin Sensitivity and Lipogenesis Resulting in Fatty Liver and Obesity

Overview
Journal Hepatology
Specialty Gastroenterology
Date 2010 Aug 28
PMID 20799351
Citations 48
Authors
Affiliations
Soon will be listed here.
Abstract

Unlabelled: Obesity is associated with chronic inflammation and contributes to the development of insulin resistance and nonalcoholic fatty liver disease. The suppressor of cytokine signaling-3 (SOCS3) protein is increased in inflammation and is thought to contribute to the pathogenesis of insulin resistance by inhibiting insulin and leptin signaling. Therefore, we studied the metabolic effects of liver-specific SOCS3 deletion in vivo. We fed wild-type (WT) and liver-specific SOCS3 knockout (SOCS3 LKO) mice either a control diet or a high-fat diet (HFD) for 6 weeks and examined their metabolic phenotype. We isolated hepatocytes from WT and SOCS3 LKO mice and examined the effects of tumor necrosis factor α and insulin on Akt phosphorylation and fatty acid metabolism and lipogenic gene expression. Hepatocytes from control-fed SOCS3 LKO mice were protected from developing tumor necrosis factor α-induced insulin resistance but also had increased lipogenesis and expression of sterol response element-binding protein-1c target genes. Lean SOCS3 LKO mice fed a control diet had enhanced hepatic insulin sensitivity; however, when fed an HFD, SOCS3 LKO mice had increased liver fat, inflammation, and whole-body insulin resistance. SOCS3 LKO mice fed an HFD also had elevated hypothalamic SOCS3 and fatty acid synthase expression and developed greater obesity due to increased food intake and reduced energy expenditure.

Conclusion: Deletion of SOCS3 in the liver increases liver insulin sensitivity in mice fed a control diet but paradoxically promotes lipogenesis, leading to the development of nonalcoholic fatty liver disease, inflammation, and obesity.

Citing Articles

Fatty acid metabolism shapes immune responses in chronic lymphocytic leukemia.

Zhang Y, Ma J, Li P, Lu K, Han Y, Hu X Biomark Res. 2025; 13(1):42.

PMID: 40075418 PMC: 11905569. DOI: 10.1186/s40364-025-00753-7.


Functional role of skeletal muscle-derived interleukin-6 and its effects on lipid metabolism.

Lin W, Song H, Shen J, Wang J, Yang Y, Yang Y Front Physiol. 2023; 14:1110926.

PMID: 37555019 PMC: 10405179. DOI: 10.3389/fphys.2023.1110926.


Alterations of SOCS1 and SOCS3 transcript levels, but not promoter methylation levels in subcutaneous adipose tissues in obese women.

Emamgholipour S, Esmaeili F, Shabani M, Hasanpour S, Pilehvari M, Zabihi-Mahmoudabadi H BMC Endocr Disord. 2023; 23(1):7.

PMID: 36609306 PMC: 9817302. DOI: 10.1186/s12902-022-01247-5.


Hepatic interleukin-1 receptor type 1 signalling regulates insulin sensitivity in the early phases of nonalcoholic fatty liver disease.

Gehrke N, Hofmann L, Straub B, Ruhle F, Waisman A, Galle P Clin Transl Med. 2022; 12(9):e1048.

PMID: 36101976 PMC: 9471277. DOI: 10.1002/ctm2.1048.


Suppressors of Cytokine Signaling and Hepatocellular Carcinoma.

Masuzaki R, Kanda T, Sasaki R, Matsumoto N, Nirei K, Ogawa M Cancers (Basel). 2022; 14(10).

PMID: 35626153 PMC: 9139988. DOI: 10.3390/cancers14102549.